Real-World Study Assessing Characteristics and Treatment Patterns of Patients With Human Epidermal Growth Factor Receptor 2 Immunohistochemistry 0 and Human Epidermal Growth Factor Receptor 2–Low Stage IV Breast Cancer: A Multicenter Retrospective St
Patient characteristics were similar between HER2-low and HER2 IHC 0 subgroups except for some differences in genetic alterations. Deterioration of PFS in later lines of therapy highlights a potential unmet need. Given the high patient attrition, the most effective treatments should be used as early as indicated as some patients may not proceed to subsequent lines of therapy.
Authors
- Sandhya Mehta (ORCID: https://orcid.org/0000-0002-9326-1693)
- David D. Stenehjem (ORCID: https://orcid.org/0000-0002-1831-285X)
- Leah Park
- Connor Willis (ORCID: https://orcid.org/0000-0001-7895-2747)
- Trang H. Au (ORCID: https://orcid.org/0000-0002-0149-0115)
- Matthew B. Schabath (ORCID: https://orcid.org/0000-0003-3241-3216)
- Clara Lam (ORCID: https://orcid.org/0000-0002-4534-7927)
- Chia Jie Tan
- Diana Brixner
- Kristen Kelley
- Xiaoqing Xu
- Jackie Kwong
- Chenghui Li
Institutions
- University of Minnesota (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Moffitt Cancer Center (US)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Japan) (JP)
- Daiichi Sankyo (United States) (US)
- University of Arkansas for Medical Sciences (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1200/po-25-00814
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00